Chief Business Officer
Mark Boyle brings over 20 years’ of executive management experience in in-vitro diagnostic and biotechnology markets to his new role in the US. Previously, he was the President of Cellestis Inc. and continued on through the acquisition by Qiagen to successfully lead the company’s global business portfolio in tuberculosis management.
During his tenure from 2001 to 2016, sales of QuantiFERON diagnostics grew to more than US$100 MM in recurring revenues. More recently, Mark was President IVD, with Clinical Genomics. Mark is based in Valencia, California.